Rain Enhancement Technolo... (RAIN)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
4.06
-0.27 (-6.24%)
At close: Jan 15, 2025, 1:41 PM
Company Description
Rain Enhancement Technologies Holdco, Inc. operates as a holding company.
The Company, through its subsidiaries, develops and commercializes ionization rainfall generation technology to provide additional rainfall for industries, supranational organizations, countries, and localities.
Rain Enhancement Technologies Holdco Inc
Country | United States |
IPO Date | Jan 2, 2025 |
Industry | Renewable Utilities |
Sector | Utilities |
Employees | n/a |
CEO | Randall P Seidl |
Contact Details
Address: 1659 Chinaberry Crt Naples, Florida United States | |
Website | https://rainwatertech.com/ |
Stock Details
Ticker Symbol | RAIN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001724979 |
CUSIP Number | |
ISIN Number | US75080J1034 |
Employer ID | 82-1130967 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Avanish Vellanki M.B.A. | Co-Founder, Chief Executive Officer & Chairman |
Buenaflor Nicolas M.P.H. | Vice President, Head Global Drug Safety & Pharmacovigilance |
Charmi Turner | Vice President of People & Culture |
Dr. Mehdi Paborji Ph.D. | Senior Vice President of Technical Operations |
Dr. Nora Ku M.D. | MD & Vice President of Clinical Development |
Dr. Richard P. Bryce | Executive Vice President & Chief Medical Officer |
Dr. Richard P. Bryce MBChB, MFPM, MRCGP | Executive Vice President & Chief Medical Officer |
Erik Atkisson | General Counsel & Chief Compliance Officer |
Josephine Bruce | Principal Financial & Accounting officer |
Joy Bruce | Principal Financial & Accounting officer |
Lucio Tozzi | Senior Vice President of Clinical Operations |
Nelson D. Cabatuan | Senior Vice President of Fin. & Admin. |
Theresa O'Connell M.S. | Director of Corporate Development & Operations |
Vijaya Tirunagaru Ph.D. | Senior Vice President & Head of Research |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Feb 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Feb 05, 2024 | 15-12G | Filing |
Feb 02, 2024 | SC 13D/A | [Amend] Filing |
Feb 02, 2024 | 4 | Filing |
Jan 29, 2024 | 4 | Filing |
Jan 29, 2024 | SC 13D/A | [Amend] Filing |
Jan 26, 2024 | S-8 POS | Filing |
Jan 26, 2024 | S-8 POS | Filing |